Science
Empowering myopia control through technology, research and evidence: Asia-Pacific Myopia Management Symposium Recap #2
Sponsored by
In this article:
Recap #2 of learnings from the Asia-Pacific Myopia Management Symposium (APMMS) 2023 by CooperVision, which explores empowering myopia control through technology, research and evidence.
In recent years, advancements in technology and a growing body of research have significantly expanded our understanding of myopia development and treatment options. It is essential for eyecare practitioners seeking to effectively manage and mitigate the progression of myopia in their patients to stay informed about global trends, leverage advanced monitoring techniques, and adopt evidence-based practices. The Asia-Pacific Myopia Management Symposium (APMMS) 2023 hosted by CooperVision explored the theme of empowering myopia control through technology, research and evidence.
This article is the second of a three-part series exploring the key themes of the symposium.
Empowering myopia control through technology, research and evidence
Myopia management is increasingly regarded as a professional imperative for eyecare practitioners due to its significant impact on public health and vision-related quality of life.1 The symposium offered insights and actionable strategies on how eyecare practitioners can engage and enhance their myopia management skills:
- Staying Informed with Global Trends: Regularly reviewing research findings and participating in global trend surveys, like those conducted by organizations such as the International Myopia Institute (IMI),2 allows clinicians to stay updated on current practices and emerging interventions in myopia management. Understanding regional differences in myopia prevalence, such as the higher prevalence in certain parts of Asia,3 can inform clinical decision-making and help tailor treatment approaches to specific populations. By staying informed about global trends, clinicians can adapt their practices to incorporate new interventions as they emerge.
- Utilizing Advanced Monitoring Techniques: Incorporating advanced monitoring techniques, such as axial length percentiles, into clinical practice can improve the assessment of myopia progression and treatment efficacy. During her lecture, Tzu Hsun Tsai from Taiwan National University mentioned that observations have shown that baseline spherical equivalent refraction and percentile change rate are effective in estimating myopia progression in certain patient groups, such as orthokeratology users. Understanding gender differences in myopia progression, such as those observed in Taiwan, can also inform treatment decisions and help tailor interventions to individual patients.
- Adopting Evidence-Based Practices: Prioritizing evidence-based practices ensures that clinicians evaluate treatment options for myopia management based on robust evidence.4 For example, randomized controlled trials (RCTs) and meta-analyses provide valuable insights into the efficacy and safety of different interventions.5 Clinicians should also consider factors such as study duration, masking, cycloplegic autorefraction, and axial length data when evaluating research studies to ensure the reliability of the evidence.
- Leveraging Long-Term Clinical Trials: Long-term studies, such as the MiSight 1-day clinical trial, provide valuable insights into the long-term efficacy and safety of myopia-controlling interventions.6 For example, data from long-term trials can show the sustained effects of interventions over time and help identify factors that may influence treatment outcomes, such as patient compliance and follow-up. Clinicians can use data from these trials to make informed decisions about treatment options for their patients.
- Using Risk Assessment Tools: Employing tools for assessing myopia development and risk of progression, such as MyKidsVision.org and Ocumetra, helps clinicians identify patients who may benefit from early intervention. These tools provide valuable information about individual patient risk factors and help tailor treatment plans accordingly. Clinicians should consider factors such as family history, age of onset, and rate of progression when assessing patient risk and determining the appropriate course of action.
- Embracing Preventative Approaches: Adopting preventative approaches, such as lifestyle changes and pharmacological interventions, can delay the onset of myopia and reduce the risk of progression. For example, studies have shown that time spent outdoors7 and atropine therapy8 can help prevent myopia onset in pre-myopic individuals. Clinicians play a crucial role in educating patients and parents about these preventative measures and promoting optimal eye health from an early age. By embracing preventative approaches, clinicians can help reduce the burden of myopia-related complications and improve long-term eye health outcomes for their patients.
The symposium emphasized the professional responsibility of eyecare practitioners to actively participate in myopia control efforts. By incorporating these strategies into their practice, eyecare practitioners can augment their capacity to successfully manage myopia, alleviate its public health implications, and enhance the quality of vision-related outcomes for their patients.
What we are still learning
As the understanding of myopia continues to evolve, so too does research methodology and consequently how it is interpreted. Historically, many studies incorporated a control arm, where participants did not receive an intervention.9,10 However, as it becomes clear that certain treatments can effectively manage or mitigate the progression of myopia, the ethics of withholding such treatments from control groups has been called into question.11 Stopping a treatment to explore potential rebound effects raises similar concerns. Furthermore, high dropout rates in control groups—particularly when blinding is inadequate—and recruitment challenges driven by parental reluctance to have their child receive a placebo, complicate research. Some recent studies have used historical controls, requiring careful adjustment for key variables like age, sex, seasonal changes, refractive error, and familial myopia history.12 Alternatives include comparisons to established treatments or employing survival analysis, where the time it takes for myopia to worsen allows early exit for placebo participants,11 though this can limit long-term efficacy assessments. Multisite studies enhance generalizability by involving diverse geographical areas and larger participant pools, yet they remain infrequent. The ongoing evolution of research methodologies in response to ethical considerations continues to be a learning area, influencing how myopia treatments are studied and ultimately how conclusive and applicable the findings are.
What this means for practice
These developments mean that clinical practice is becoming more dynamic, precise, and responsive to individual patient needs, enhancing both the effectiveness of treatments and the overall patient experience. Empowering myopia control through the integration of technology, research, and evidence is vital. The strategies provided by the Asia-Pacific Myopia Management Symposium are easily actionable by all eyecare practitioners to alleviate the global burden of myopia.
Meet the Authors:
About Jeanne Saw
Jeanne is a clinical optometrist based in Sydney, Australia. She has worked as a research assistant with leading vision scientists, and has a keen interest in myopia control and professional education.
As Manager, Professional Affairs and Partnerships, Jeanne works closely with Dr Kate Gifford in developing content and strategy across Myopia Profile's platforms, and in working with industry partners. Jeanne also writes for the CLINICAL domain of MyopiaProfile.com, and the My Kids Vision website, our public awareness platform.
This content is brought to you thanks to unrestricted educational grant from
References
- Sankaridurg P, Tahhan N, Kandel H, Naduvilath T, Zou H, Frick KD, Marmamula S, Friedman DS, Lamoureux E, Keeffe J, Walline JJ, Fricke TR, Kovai V, Resnikoff S. IMI Impact of Myopia. Invest Ophthalmol Vis Sci. 2021 Apr 28;62(5):2.
- Wolffsohn JS, Whayeb Y, Logan NS, Weng R; International Myopia Institute Ambassador Group*. IMI-Global Trends in Myopia Management Attitudes and Strategies in Clinical Practice-2022 Update. Invest Ophthalmol Vis Sci. 2023 May 1;64(6):6.
- Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo KS, Sankaridurg P, Wong TY, Naduvilath TJ, Resnikoff S. Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050. Ophthalmology. 2016 May;123(5):1036-42.
- Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. BMJ. 1996 Jan 13;312(7023):71-2. doi: 10.1136/bmj.312.7023.71.
- Zabor EC, Kaizer AM, Hobbs BP. Randomized Controlled Trials. Chest. 2020 Jul;158(1S):S79-S87.
- Lumb E, Sulley A, Logan NS, Jones D, Chamberlain P. Six years of wearer experience in children participating in a myopia control study of MiSight® 1 day. Cont Lens Anterior Eye. 2023 Aug;46(4):101849.
- Wang B, Watt K, Chen Z, Kang P. Predicting the child who will become myopic - can we prevent onset? Clin Exp Optom. 2023 Nov;106(8):815-824.
- Yam JC, Zhang XJ, Zhang Y, Yip BHK, Tang F, Wong ES, Bui CHT, Kam KW, Ng MPH, Ko ST, Yip WWK, Young AL, Tham CC, Chen LJ, Pang CP. Effect of Low-Concentration Atropine Eyedrops vs Placebo on Myopia Incidence in Children: The LAMP2 Randomized Clinical Trial. JAMA. 2023 Feb 14;329(6):472-481.
- Yen MY, Liu JH, Kao SC, Shiao CH. Comparison of the effect of atropine and cyclopentolate on myopia. Ann Ophthalmol. 1989 May;21(5):180-2, 187.
- Berntsen DA, Barr CD, Mutti DO, Zadnik K. Peripheral defocus and myopia progression in myopic children randomly assigned to wear single vision and progressive addition lenses. Invest Ophthalmol Vis Sci. 2013 Aug 27;54(8):5761-70.
- Bullimore MA, Brennan NA, Flitcroft DI. The future of clinical trials of myopia control. Ophthalmic Physiol Opt. 2023 May;43(3):525-533.
- Lam CS, Tang WC, Lee PH, Zhang HY, Qi H, Hasegawa K, To CH. Myopia control effect of defocus incorporated multiple segments (DIMS) spectacle lens in Chinese children: results of a 3-year follow-up study. Br J Ophthalmol. 2022 Aug;106(8):1110-1114.
Enormous thanks to our visionary sponsors
Myopia Profile’s growth into a world leading platform has been made possible through the support of our visionary sponsors, who share our mission to improve children’s vision care worldwide. Click on their logos to learn about how these companies are innovating and developing resources with us to support you in managing your patients with myopia.